Contineum therapeutics announces appointment of sarah boyce to board of directors

San diego--(business wire)--contineum therapeutics, inc. (nasdaq: ctnm), a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies that target biological pathways associated with specific clinical impairments for the treatment of neuroscience, inflammation and immunology (ni&i) indications, today announced the appointment of sarah boyce, president and chief executive officer of avidity biosciences, inc. (nasdaq: rna), as an indepen.
RNA Ratings Summary
RNA Quant Ranking